The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats.
The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats.
复制标题
DOI：
10.1093/ofid/ofac641
复制
发表时间：
2022-12
影响因子：
4.2
通讯作者：
中科院分区：
文献类型：
--
作者：
由严重急性呼吸系统综合征冠状病毒2 （SARS-CoV-2）引起的2019年冠状病毒病（COVID-19）大流行表明，有必要广泛共享数据和生物标本，以优化美国退伍军人的临床结果。作为回应，退伍军人健康管理局建立了VA SHIELD（对抗传染病和新出现的危及生命的疾病的科学与健康倡议），这是一个全面的生物标本和临床数据库，来自受影响的退伍军人，以推进研究和公共卫生监督，并提高诊断和治疗能力。VA SHIELD现在包括12个站点，收集受SARS-CoV-2影响的美国退伍军人的去鉴定生物标本。此外，在退伍军人事务研究与发展办公室的指导下，还建立了2个生物储存点、1个数据处理中心和1个协调中心。VA SHIELD的第一阶段包括34157个样本。其中，83.8%的人对SARS-CoV-2的检测呈阳性，其余的人作为同期对照。样本包括鼻咽拭子（57.9%）、血浆（27.9%）和血清（12.5%）。相关的临床和人口统计信息允许在患者人口统计、临床经验和管理、疫苗接种和合并症的背景下评估生物学数据。VA SHIELD是美国国家多样性的代表，具有影响国家医疗保健的巨大潜力。VA SHIELD将支持旨在更好地了解SARS-CoV-2和其他紧急医疗危机的未来项目。VA SHIELD将在可能的范围内促进诊断和治疗方法的发现，以降低COVID-19的发病率和死亡率，并减少新出现的威胁对美国退伍军人和全球人口健康的影响。美国退伍军人事务部建立了一个生物库，为COVID-19的研究提供生物标本和数据，同时为随后出现的危及生命的疾病做准备。这些资源可供调查人员研究COVID-19和未来新出现的疾病。
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide. The US Department of Veterans Affairs has implemented a biorepository providing biological specimens and data for studies of COVID-19, while simultaneously preparing for subsequent emerging life-threatening diseases. These resources are available for investigators to study COVID-19 and future emerging diseases.
登录
查看更多内容
影响因子：
64.8
作者：
Bycroft C;Freeman C;Petkova D;Band G;Elliott LT;Sharp K;Motyer A;Vukcevic D;Delaneau O;O'Connell J;Cortes A;Welsh S;Young A;Effingham M;McVean G;Leslie S;Allen N;Donnelly P;Marchini J
通讯作者：
Marchini J
影响因子：
13.8
作者：
Ioannou GN;Locke E;Green P;Berry K;O'Hare AM;Shah JA;Crothers K;Eastment MC;Dominitz JA;Fan VS
通讯作者：
Fan VS
DOI：
10.1016/j.atg.2014.04.001
发表时间：
2014-06-01
期刊：
Applied & translational genomics
影响因子：
--
作者：
Branković I;Malogajski J;Morré SA
通讯作者：
Morré SA
影响因子：
3.7
作者：
Song RJ;Ho YL;Schubert P;Park Y;Posner D;Lord EM;Costa L;Gerlovin H;Kurgansky KE;Anglin-Foote T;DuVall S;Huffman JE;Pyarajan S;Beckham JC;Chang KM;Liao KP;Djousse L;Gagnon DR;Whitbourne SB;Ramoni R;Muralidhar S;Tsao PS;O'Donnell CJ;Gaziano JM;Casas JP;Cho K;VA Million Veteran Program COVID-19 Science Initiative
通讯作者：
VA Million Veteran Program COVID-19 Science Initiative
影响因子：
3.7
作者：
Whitbourne, Stacey B.;Nguyen, Xuan-Mai T.;Song, Rebecca J.;Lord, Emily;Lyden, Michelle;Harrington, Kelly M.;Ward, Rachel;Li, Yanping;Brewer, Jessica V. V.;Cho, Kelly M.;Djousse, Luc;Muralidhar, Sumitra;Tsao, Philip S.;Gaziano, J. Michael;Casas, Juan P.
通讯作者：
Casas, Juan P.